CTT PHARMACEUTICAL HLDGS (CTTH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Sep 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CTTH SEC filings page.
This page shows CTT PHARMACEUTICAL HLDGS (CTTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CTT's FY2025 numbers describe a small balance sheet with a near-term funding gap, while missing operating lines prevent judging how the business earns or uses cash.
FY2025 supplies a balance-sheet snapshot of assets worth$86K but no revenue, earnings, or cash-flow lines, so profitability and cash conversion cannot be assessed. Compared with FY2011, liabilities were a smaller share of assets by FY2025, but the asset base contracted to$86K , meaning the lower burden also reflects a much smaller reported footprint.
The FY2025 current ratio was 0.5x, meaning near-term assets did not cover near-term liabilities. That is a working-capital constraint, not a measure of operating strength; with no cash balance supplied, the accounts cannot quantify how the mismatch is funded.
Equity was
Financial Health Signals
CTT PHARMACEUTICAL HLDGS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2026.
Cash & Balance Sheet
CTT PHARMACEUTICAL HLDGS held $31 in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
CTTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q4'2510-Q | Q3'1510-K | Q2'1510-Q | Q1'1510-Q | Q4'1410-K | Q3'1410-K | Q2'1410-Q |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | N/A | N/A | $15K+15.4% | $4K+387.6% | $35K+3745.9% | N/A | $13K+1227.8% | $916-96.7% |
| Operating Income | N/A | N/A | N/A | N/A | -$337K-20046.6% | N/A | N/A | -$22K+64.3% |
| Net Income | N/A | N/A | -$342K-691.6% | -$363K-39319.2% | -$337K-20046.6% | N/A | -$43K-409.8% | -$920+98.6% |
| EPS (Basic) | N/A | N/A | N/A | N/A | N/A | N/A | $0.01+200.0% | $0.00+100.0% |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0.00 |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 22M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, Income Tax.
CTTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q4'2510-Q | Q3'1510-K | Q2'1510-Q | Q1'1510-Q | Q4'1410-K | Q3'1410-K | Q2'1410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $67K | $86K | $922K+605.2% | $1.2M+420.0% | $1.4M+8140.0% | $1.7M | $131K+1787.8% | $228K+1478.4% |
| Current Assets | $31 | $15K | $922K | $959K | $1.0M | $1.0M+16690.4% | N/A | N/A |
| Cash & Equivalents | $31 | $15K | $32K-74.4% | $46K+1155.7% | $73K+1516.0% | $81K | $125K | $4K-53.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | N/A | N/A | $5K | $5K | $5K | $5K | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $41K | $31K | $184K+47.6% | $156K+10.1% | $212K-24.4% | $169K+478.0% | $125K-74.9% | $142K-71.1% |
| Current Liabilities | $41K | $31K | N/A | N/A | N/A | N/A | N/A | N/A |
| Non-Current Liabilities | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $26K | $55K | $738K+11905.2% | $1.0M+1100.3% | $1.2M+559.6% | $1.5M+5191.3% | $6K+101.3% | $86K+118.0% |
| Retained Earnings | -$7.7M | -$7.6M | -$1.9M-724.7% | -$1.6M | -$1.2M | -$867K-344.3% | -$231K | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CTTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q4'2510-Q | Q3'1510-K | Q2'1510-Q | Q1'1510-Q | Q4'1410-K | Q3'1410-K | Q2'1410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$16K+35.9% | -$29K-1.5% | -$40K-11915.8% | -$47K-22310.0% | -$24K+0.7% | -$29K+15.2% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | $44K | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | -$1-100.0% | $271K+1414.9% | -$148K-748.1% |
| Financing Cash Flow | N/A | N/A | -$959+80.3% | $3K-99.3% | $29K+485.6% | N/A | -$5K | $387K |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CTTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q4'2510-Q | Q3'1510-K | Q2'1510-Q | Q1'1510-Q | Q4'1410-K | Q3'1410-K | Q2'1410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | -46.3%+656.3pp | -35.3%-34.2pp | -27.9% | N/A | -702.6% | -1.1% |
| Return on Assets | N/A | N/A | -37.1%-4.0pp | -30.6%-30.3pp | -23.8%-14.0pp | N/A | -33.0%+89.3pp | -0.4%+441.5pp |
| Current Ratio | 0.00 | 0.50 | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 1.59 | 0.56 | 0.25-20.0x | 0.15-1.5x | 0.18 | 0.11 | 20.27 | 1.66 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CTT PHARMACEUTICAL HLDGS CTTH | FY2025 | N/A | N/A | N/A | $3.3M | — |
| TILT HLDGS INC TLLTF | FY2024 | $115.6M | -$99.7M | -86.2% | $44K | — |
| BODY AND MIND INC BMMJ | FY2023 | $22.8M | -$20.6M | -90.1% | $495K | — |
Where CTT PHARMACEUTICAL HLDGS Ranks
Frequently Asked Questions
What are CTT PHARMACEUTICAL HLDGS's total assets?
CTT PHARMACEUTICAL HLDGS (CTTH) had $86K in total assets as of fiscal year 2025, including both current and long-term assets.
What is CTT PHARMACEUTICAL HLDGS's current ratio?
CTT PHARMACEUTICAL HLDGS (CTTH) had a current ratio of 0.50 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is CTT PHARMACEUTICAL HLDGS's debt-to-equity ratio?
CTT PHARMACEUTICAL HLDGS (CTTH) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CTT PHARMACEUTICAL HLDGS's P/E ratio?
CTT PHARMACEUTICAL HLDGS (CTTH) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $3.3M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CTT PHARMACEUTICAL HLDGS's price-to-sales ratio?
CTT PHARMACEUTICAL HLDGS (CTTH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $3.3M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.